ABCC4 and colorectal carcinoma: Interestingly, irinotecan, a chemotherapeutic drug for CRC, has a high affinity for ABCC4 and was demonstrated (through substrate competition with cAMP) to increase cAMP levels at or near the plasma membrane to levels comparable with the effect of the ABCC family inhibitor MK571 [33].